Overview

Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, immunogenicity, and antiviral effects of multiple intravenous doses of ANZ-521 in patients with chronic Hepatitis C virus.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Anza Therapeutics, Inc.